Trial reportAlcoholism, clinical and experimental research2012
Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings.
Trial report in Alcoholism, clinical and experimental research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy.Psychopharmacology · 2024Pooled it
- Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder.Addiction biology · 2022Trial
- Sleep moderates the relationship between stress and craving in individuals with opioid use disorder.Experimental and clinical psychopharmacology · 2021Trial
- Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.The American journal of psychiatry · 2021Trial
- Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.Alcoholism, clinical and experimental research · 2020Trial
- Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.Alcoholism, clinical and experimental research · 2020Trial
- Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder.NeuroImage. Clinical · 2020Trial
- A day-by-day prospective analysis of stress, craving and risk of next day alcohol intake during alcohol use disorder treatment.Drug and alcohol dependence · 2019Trial
- Acute prazosin administration does not reduce stressor reactivity in healthy adults.Psychopharmacology · 2019Trial
- Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.Alcoholism, clinical and experimental research · 2019Trial
- Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.The American journal of psychiatry · 2018Trial
- A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco-deprived and -satiated smokers.Human psychopharmacology · 2018Trial
- Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin.Drug and alcohol dependence · 2017Trial
- The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.Addiction biology · 2016Trial
- A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.Alcoholism, clinical and experimental research · 2015Trial
- Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.Alcoholism, clinical and experimental research · 2015Trial
- The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.Psychopharmacology · 2013Trial
- A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.Journal of addiction medicineTrial
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundStress, alcohol cues, and dysregulated stress responses increase alcohol craving and relapse susceptibility, but few pharmacologic agents are known to decrease stress- and cue-induced alcohol craving and associated stress dysregulation in humans. Here we report findings from a preliminary efficacy study of the alpha-1 receptor antagonist, prazosin, in modulating these relapse-relevant factors in alcohol-dependent individuals.
methodsSeventeen early abstinent, treatment-seeking alcohol-dependent individuals (12 men and 5 women) were randomly assigned to receive either placebo or 16 mg daily prazosin in a double-blind, placebo-controlled manner over 4 weeks. During week 4, all patients participated in a 3-day laboratory experiment involving 5-minute guided imagery exposure to stress, alcohol cue, and neutral-relaxing/control conditions, 1 exposure per day, on consecutive days in a random, counterbalanced order. Alcohol craving, anxiety, negative emotion, cardiovascular measures, and plasma hypothalamic-pituitary-adrenal (HPA; cortisol, adenocorticotropic hormone) were assessed repeatedly in each session.
resultsThe prazosin group (n = 9) versus the placebo group (n = 8) showed significantly lower alcohol craving, anxiety, and negative emotion following stress exposure. The placebo group also showed significantly increased stress- and cue-induced alcohol craving, anxiety, negative emotion, and blood pressure (BP), as well as a blunted HPA response relative to the neutral condition, while the prazosin group showed no such increases in craving, anxiety, negative emotion, and BP, and no blunted HPA response to stress and alcohol cue exposure.
conclusionsPrazosin appears efficacious in decreasing stress- and cue-induced alcohol craving and may normalize the stress dysregulation associated with early recovery from alcoholism. Further research to assess the efficacy of prazosin in reducing alcohol craving and stress-related relapse risk is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.